Payment overview · 2025
General Payments
$810.82
55 reported records · 5 companies
Healthcare provider profile · identity verified
Joseph Maglio, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GRANBY, CT · NPI 1063517282
Verified facts
What the public records show
CMS Open Payments records show Joseph Maglio, MD received $810.82 in general payments during 2025 across 55 reported records.
Abbott Laboratories accounted for 43.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $348.61 | 43.0% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $311.96 | 38.5% | 33 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.59 | 10.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.74 | 4.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $30.92 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $810.82 | 55 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $348.61 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $311.96 | 33 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $311.96 | 33 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $85.59 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $64.66 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.74 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 122 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 734 | 198 |
| Amlodipine Besylate | Amlodipine Besylate | 636 | 169 |
| Lisinopril | Lisinopril | 594 | 154 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 362 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 330 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 68 |
| Losartan Potassium | Losartan Potassium | 210 | 58 |
| Simvastatin | Simvastatin | 190 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 52 |
| Trazodone Hcl | Trazodone Hcl | 162 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 38 |
| Gabapentin | Gabapentin | 140 | 35 |
| Eliquis | Apixaban | 122 | 22 |
| Metformin Hcl Er | Metformin Hcl | 122 | 34 |
| Allopurinol | Allopurinol | 115 | 30 |
| Clonazepam | Clonazepam | 113 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 31 |
| Prednisone | Prednisone | 111 | 68 |
| Omeprazole | Omeprazole | 107 | 33 |
| Metformin Hcl | Metformin Hcl | 104 | 28 |
| Bupropion Xl | Bupropion Hcl | 103 | 27 |
| Alprazolam | Alprazolam | 100 | 33 |
| Sertraline Hcl | Sertraline Hcl | 99 | 26 |
| Ezetimibe | Ezetimibe | 94 | 31 |
| Lorazepam | Lorazepam | 90 | 28 |
| Irbesartan | Irbesartan | 89 | 25 |
| Chlorthalidone | Chlorthalidone | 85 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 23 |
| Tramadol Hcl | Tramadol Hcl | 77 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 16 |
| Famotidine | Famotidine | 75 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 31 |
| Meloxicam | Meloxicam | 68 | 38 |
| Ozempic | Semaglutide | 68 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 15 |
| Synthroid | Levothyroxine Sodium | 65 | 18 |
| Xarelto | Rivaroxaban | 63 | 11 |
| Azithromycin | Azithromycin | 60 | 55 |
| Atenolol | Atenolol | 59 | 17 |
| Furosemide | Furosemide | 52 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 14 |
| Mirtazapine | Mirtazapine | 50 | 18 |
| Nateglinide | Nateglinide | 50 | 11 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Carvedilol | Carvedilol | 43 | 12 |
| Finasteride | Finasteride | 43 | 12 |
| Januvia | Sitagliptin Phosphate | 43 | 11 |
| Telmisartan | Telmisartan | 42 | 14 |
| Alendronate Sodium | Alendronate Sodium | 40 | 14 |
| Donepezil Hcl | Donepezil Hcl | 40 | 11 |
| Tradjenta | Linagliptin | 40 | suppressed |
| Jardiance | Empagliflozin | 39 | 12 |
| Potassium Chloride | Potassium Chloride | 38 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 12 |
| Valsartan | Valsartan | 34 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 28 |
| Valacyclovir | Valacyclovir Hcl | 33 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 31 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 30 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 12 |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 23 |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Loperamide | Loperamide Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 15 |
| Celecoxib | Celecoxib | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Metaxalone | Metaxalone | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $810.82 · 55 records | Abbott Laboratories | ELIQUIS, FREESTYLE LIBRE 3, NURTEC ODT, QULIPTA, TEPEZZA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error